Abstract | BACKGROUND: METHODS: RESULTS:
Naringenin (0.1, 1, 10 μmol/L) inhibited cardiomyocyte hypertrophy in a concentration-dependent manner (P < 0.05), up-regulated the expressions of PPARα, PPARβ, PPARγ and CYP2J3 (P < 0.05), and increased the level of 14,15-EET (P < 0.05). PPOH, a CYP2J3 inhibitor, blocked the naringenin-mediated improvement of myocardial hypertrophy (P < 0.01), and abolished the up-regulation of PPARs expressions (P < 0.01). Meanwhile, MK886, a PPARα antagonist, GSK0660, a PPARβ antagonist, and GW9662, a PPARγ antagonist, reversed the protection of naringenin on cardiomyocytes (P < 0.05), and abrogated the up-regulation of CYP2J3-EET produced by naringenin (P < 0.05). CONCLUSIONS: Activation of EETs and PPARs function together may be contributed to the anti-hypertrophic effect of naringenin in H9c2 cells under high glucose condition.
|
Authors | Jie Zhang, Hongmei Qiu, Jiajun Huang, Shumei Ding, Bo Huang, Ping Zhou, Qingsong Jiang |
Journal | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
(Biomed Pharmacother)
Vol. 109
Pg. 1498-1505
(Jan 2019)
ISSN: 1950-6007 [Electronic] France |
PMID | 30551401
(Publication Type: Journal Article)
|
Copyright | Copyright © 2018 Elsevier Masson SAS. All rights reserved. |
Chemical References |
- Flavanones
- PPAR gamma
- RNA, Messenger
- Atrial Natriuretic Factor
- naringenin
- Glucose
|
Topics |
- Animals
- Atrial Natriuretic Factor
(metabolism)
- Cardiomegaly
(chemically induced, drug therapy, metabolism)
- Cell Line
- Diabetic Cardiomyopathies
(chemically induced, drug therapy, metabolism)
- Flavanones
(pharmacology)
- Glucose
(adverse effects)
- Myocytes, Cardiac
(drug effects, metabolism)
- PPAR gamma
(metabolism)
- RNA, Messenger
(metabolism)
- Rats
- Signal Transduction
(drug effects)
- Up-Regulation
(drug effects)
|